MIAMI, May 20, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), ( SAB or the Company ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is…
Read More: https://www.globenewswire.com/news-release/2024/05/20/2885182/0/en/SAB-Biotherapeutics-Announces-Q1-2024-Financial-Results-and-Provides-Company-Updates.html
Stay updated with the latests analysis and insights fromm etfsector.com